Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments
20/04/2026 13:38
April 20 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA INC - SCHEDULES TYPE C FDA MEETING FOR HARMONIC PROTOCOL AMENDMENTS LANTERN PHARMA INC - LP-300 DEMONSTRATES 8.3-MONTH MEDIAN PROGRESSION-FREE SURVIVAL WITH NO ADDED TOXICITY Source text: ID:nBwW0fsGa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview